Drug Approval | June 09, 2026
FDA expands Pfizer’s HYMPAVZI approval
Broadening access for children & patients with inhibitor-complicated hemophilia
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The session created a platform for meaningful discussions on the challenges of the disease and the importance of timely intervention
Donor families honoured as Apollo highlights over 27,500 transplants performed and calls for greater public participation in organ donation
Amitabh Dube and Sheetal Arora named Co-Chairmen for the forthcoming term
The approved product is therapeutically equivalent to Haldol tablets of Ortho McNeil Pharmaceutical
Approval for generic version of Xeljanz enables immediate launch and strengthens Aurobindo’s U.S. portfolio with its 586th ANDA approval
Multi-target licensing agreement combines Stipple Bio’s epitope discovery platform with Lonza’s ADC technologies to develop targeted cancer treatments
MSD joins as anchor customer as Aurobindo strengthens its position in the fast-growing global biologics manufacturing market
The drug currently approved for chronic kidney disease (CKD) associated with type 2 diabetes, may benefit a much broader group of patients than previously recognized
Subscribe To Our Newsletter & Stay Updated
